Profile data is unavailable for this security.
About the company
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.
- Revenue in USD (TTM)8.55m
- Net income in USD-27.62m
- Incorporated1998
- Employees58.00
- LocationDURECT Corp10240 Bubb RoadCUPERTINO 95014United StatesUSA
- Phone+1 (408) 777-1417
- Fax+1 (408) 777-3577
- Websitehttps://www.durect.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aprea Therapeutics Inc | 583.24k | -14.29m | 28.51m | 7.00 | -- | 1.16 | -- | 48.88 | -4.00 | -4.00 | 0.1613 | 4.89 | 0.0221 | -- | -- | 83,320.00 | -54.11 | -68.66 | -63.19 | -77.19 | -- | -- | -2,449.55 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
| RenovoRx Inc | 0.00 | -10.23m | 28.98m | 8.00 | -- | -- | -- | -- | -1.01 | -1.01 | 0.00 | -0.2805 | 0.00 | -- | -- | 0.00 | -234.38 | -- | -317.07 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -3.47 | -- | -- | -- |
| Spruce Biosciences Inc | 10.09m | -47.92m | 29.52m | 29.00 | -- | 0.3847 | -- | 2.93 | -1.26 | -1.26 | 0.2622 | 1.86 | 0.1064 | -- | -- | 347,896.60 | -50.55 | -41.24 | -62.77 | -46.49 | -- | -- | -474.96 | -1,774.39 | -- | -107.65 | 0.0418 | -- | -- | -- | -3.77 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -17.19m | 29.69m | 29.00 | -- | -- | -- | -- | -0.4079 | -0.4079 | 0.00 | -0.0803 | 0.00 | -- | -- | 0.00 | -271.62 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| Earth Science Tech Inc | 5.98m | 330.94k | 29.91m | 8.00 | 98.96 | 13.86 | 56.51 | 5.00 | 0.001 | 0.001 | 0.0195 | 0.0069 | 3.16 | 11.41 | 106.07 | 747,970.00 | 17.50 | -224.84 | 42.70 | -- | 62.29 | 37.79 | 5.53 | -333.58 | 0.386 | -0.3899 | 0.1023 | -- | 243.77 | -36.31 | -111.95 | -- | -- | -- |
| DURECT Corp | 8.55m | -27.62m | 30.01m | 58.00 | -- | 1.98 | -- | 3.51 | -1.12 | -1.12 | 0.3257 | 0.4873 | 0.1624 | 0.7927 | 3.65 | 147,379.30 | -52.47 | -37.34 | -124.79 | -53.44 | 79.91 | 91.83 | -323.16 | -139.11 | 1.20 | -55.63 | 0.5299 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
| Aptorum Group Ltd | 1.20m | -13.40m | 30.09m | 18.00 | -- | 1.30 | -- | 25.08 | -3.64 | -3.64 | 0.3234 | 4.22 | 0.0624 | 74.87 | 17.36 | 66,656.11 | -80.15 | -42.74 | -68.67 | -46.93 | 7.33 | -2.90 | -1,283.55 | -1,477.58 | 1.32 | -94.53 | 0.0066 | -- | -15.95 | -- | 60.88 | -- | -42.83 | -- |
| Singular Genomics Systems Inc | 2.91m | -94.82m | 30.10m | 255.00 | -- | 0.1679 | -- | 10.34 | -1.30 | -1.30 | 0.04 | 2.42 | 0.0098 | 0.2182 | 3.94 | 11,415.69 | -31.96 | -- | -33.80 | -- | -19.17 | -- | -3,257.30 | -- | 9.77 | -- | 0.0474 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| Palatin Technologies, Inc. | 7.10m | -30.91m | 30.18m | 34.00 | -- | -- | -- | 4.25 | -2.48 | -2.48 | 0.5582 | -0.7956 | 0.3118 | 0.8717 | 3.42 | 208,755.90 | -135.79 | -26.11 | -269.84 | -30.68 | 95.34 | -- | -435.53 | -126.20 | 1.09 | -- | -- | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
| Nymox Pharmaceutical Corp | 0.00 | -4.87m | 30.29m | 3.00 | -- | -- | -- | -- | -0.0536 | -0.0536 | 0.00 | -0.0204 | 0.00 | -- | -- | -- | -255.75 | -264.40 | -- | -464.48 | -- | -- | -- | -13,001.67 | -- | -42.44 | -- | -- | -- | -- | 47.55 | -- | -- | -- |
| Janone Inc | 0.00 | -17.10m | 30.51m | 5.00 | -- | -- | -- | -- | -3.52 | -0.4564 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -52.40 | -23.12 | -96.58 | -62.22 | -- | 23.38 | -- | -30.14 | -- | -- | 0.0594 | -- | -- | -- | -313.15 | -- | -- | -- |
| Sensei Biotherapeutics Inc | 0.00 | -34.10m | 31.59m | 27.00 | -- | 0.486 | -- | -- | -1.21 | -1.21 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -35.38 | -47.03 | -38.31 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0247 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
| Surrozen Inc | 0.00 | -43.04m | 31.64m | 42.00 | -- | 0.5378 | -- | -- | -21.35 | -21.35 | 0.00 | 18.39 | 0.00 | -- | -- | 0.00 | -63.52 | -- | -72.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.08m | 31.75m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to DURECT Corp's reporting currency: US Dollar USD
18.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Ingalls & Snyder LLCas of 31 Dec 2023 | 2.15m | 7.19% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.06m | 3.57% |
| Richmond Brothers, Inc.as of 31 Dec 2023 | 518.29k | 1.74% |
| Gagnon Securities LLCas of 31 Dec 2023 | 358.71k | 1.20% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 334.30k | 1.12% |
| Beirne Wealth Consulting Services LLCas of 31 Dec 2023 | 320.05k | 1.07% |
| Dalton Investments LLCas of 31 Dec 2023 | 237.33k | 0.80% |
| Geode Capital Management LLCas of 31 Dec 2023 | 234.36k | 0.79% |
| Tocqueville Asset Management LPas of 31 Dec 2023 | 231.22k | 0.78% |
| Ironwood Investment Management LLCas of 31 Dec 2023 | 195.52k | 0.66% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
